Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	TGX221	1	72	flat	flat	BT20 TGX-221 0 1 72	8	1.988	Inf	1.02	-0.00357	0.0	1.02	0.01	-0.00762	1.0	1.0	Inf	1.02	1.0	1.02	0.01	-0.00881	1.0	1.0
BT-20	TGX221	2	72	flat	flat	BT20 TGX-221 0 2 72	8	1.656	Inf	1.0	0.0477	0.0	1.0	0.01	-0.101	1.0	0.946	Inf	1.0	0.961	1.0	0.01	-0.101	1.0	0.956
BT-20	TGX221	3	72	flat	flat	BT20 TGX-221 0 3 72	8	2.469	Inf	1.01	0.0147	0.0	1.01	0.01	-0.0563	1.0	0.982	Inf	1.01	0.983	1.01	0.01	-0.0552	1.0	0.979
BT-20	Everolimus	3	72	flat	flat	BT20 everolimus 0 3 72	8	2.422	Inf	0.475	0.456	0.0	0.475	0.01	0.602	0.0632	0.543	Inf	0.478	0.534	0.478	0.01	0.561	0.0844	0.534
BT-549	Sirolimus	2	72	flat	flat	BT549 rapamycin 0 2 72	8	1.830	Inf	0.569	0.384	0.0	0.569	0.01	0.517	0.113	0.618	Inf	0.642	0.677	0.642	0.01	0.465	0.153	0.679
BT-549	Sirolimus	3	72	flat	flat	BT549 rapamycin 0 3 72	8	1.703	Inf	0.455	0.482	0.0	0.455	0.01	0.376	0.243	0.518	Inf	0.582	0.626	0.582	0.01	0.436	0.179	0.625
HCC38	Alpelisib	1	72	flat	flat	HCC38 alpelisib 0 1 72	8	1.738	Inf	0.757	0.0835	0.0	0.757	0.01	0.593	0.0674	0.909	Inf	0.798	0.929	0.798	0.01	0.579	0.0744	0.923
HCC38	Alpelisib	2	72	flat	flat	HCC38 alpelisib 0 2 72	8	2.086	Inf	0.848	0.0559	0.0	0.848	0.01	-0.0371	1.0	0.931	Inf	0.848	0.944	0.848	0.01	-0.0359	1.0	0.932
BT-20	KIN001-244	1	72	flat	flat	BT20 KIN001-244 0 1 72	8	2.125	Inf	0.911	0.0401	0.0	0.911	0.01	-0.00641	1.0	0.957	Inf	0.908	0.958	0.908	0.01	-0.00745	1.0	0.955
BT-549	XL147	3	72	flat	flat	BT549 pilaralisib 0 3 72	8	1.772	Inf	0.933	0.0351	0.0	0.933	0.01	-0.0699	1.0	0.962	Inf	0.941	0.969	0.941	0.01	-0.0712	1.0	0.967
HCC70	Everolimus	1	72	flat	flat	HCC70 everolimus 0 1 72	8	1.366	Inf	0.569	0.354	0.0	0.569	0.01	0.623	0.0534	0.643	Inf	0.718	0.766	0.718	0.01	0.62	0.0547	0.765
BT-549	Everolimus	2	72	flat	flat	BT549 everolimus 0 2 72	8	1.909	Inf	0.566	0.407	0.0	0.566	0.01	-0.646	1.0	0.594	Inf	0.627	0.648	0.627	0.01	-1.01	1.0	0.649
BT-20	BX-912	1	72	flat	flat	BT20 BX-912 0 1 72	8	2.193	Inf	0.858	0.0928	0.0	0.858	0.01	0.25	0.422	0.903	Inf	0.851	0.901	0.851	0.01	0.243	0.433	0.897
BT-549	Alpelisib	3	72	flat	flat	BT549 alpelisib 0 3 72	8	1.743	Inf	0.817	0.068	0.0	0.817	0.01	-0.0192	1.0	0.915	Inf	0.846	0.942	0.846	0.01	-0.0162	1.0	0.928
BT-549	XL147	1	72	flat	flat	BT549 pilaralisib 0 1 72	8	1.855	Inf	0.941	0.0385	0.0	0.941	0.01	-0.0931	1.0	0.954	Inf	0.946	0.965	0.946	0.01	-0.0808	1.0	0.958
BT-20	XL147	1	72	flat	flat	BT20 pilaralisib 0 1 72	8	2.128	Inf	0.815	0.048	0.0	0.815	0.01	0.411	0.205	0.939	Inf	0.813	0.95	0.813	0.01	0.383	0.234	0.937
BT-20	XL147	2	72	flat	flat	BT20 pilaralisib 0 2 72	8	1.784	Inf	0.759	0.073	0.0	0.759	0.01	-0.0058	1.0	0.907	Inf	0.796	0.937	0.796	0.01	-0.00637	1.0	0.92
BT-20	XL147	3	72	flat	flat	BT20 pilaralisib 0 3 72	8	2.647	Inf	0.755	0.102	0.0	0.755	0.01	0.0679	0.81	0.885	Inf	0.708	0.871	0.708	0.01	0.0505	0.856	0.857
HCC38	Alpelisib	3	72	flat	flat	HCC38 alpelisib 0 3 72	8	1.398	Inf	0.75	0.0995	0.0	0.75	0.01	0.141	0.634	0.883	Inf	0.829	0.932	0.829	0.01	0.113	0.698	0.92
HCC38	Everolimus	1	72	sigmoid	flat	HCC38 everolimus 0 1 72	8	1.703	11.8	0.54	0.428	0.000126	0.341	0.1	0.688	0.0303	NA	Inf	0.641	0.664	0.641	0.01	0.571	0.0788	0.665
BT-20	BX-912	3	72	flat	flat	BT20 BX-912 0 3 72	8	2.619	Inf	0.904	0.0795	0.0	0.904	0.01	0.000173	0.999	0.918	Inf	0.879	0.9	0.879	0.01	0.00619	0.982	0.896
BT-549	Everolimus	3	72	sigmoid	flat	BT549 everolimus 0 3 72	8	1.587	59.5	0.533	0.425	1e-05	0.395	0.1	0.702	0.0264	NA	Inf	0.656	0.685	0.656	0.01	0.48	0.141	0.685
BT-549	AS605240	2	72	flat	flat	BT549 AS-605240 0 2 72	8	1.961	Inf	0.91	0.0479	0.0	0.91	0.01	0.414	0.201	0.949	Inf	0.914	0.954	0.914	0.01	0.418	0.197	0.951
Hs 578T	Sirolimus	3		flat	flat	Hs578T rapamycin 3	8	2.836	Inf	0.675	0.309	0.0	0.675	0.01	-1.79	1.0	0.691	Inf	0.604	0.621	0.604	0.01	-3.02	1.0	0.621
Hs 578T	Sirolimus	2		flat	flat	Hs578T rapamycin 2	8	2.536	Inf	0.623	0.341	0.0	0.623	0.01	0.16	0.593	0.66	Inf	0.589	0.623	0.589	0.01	-0.232	1.0	0.624

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)